Clinical Trials Logo

Clinical Trial Summary

The FCCSS is a multicentric national large-scale collaborative population-based study of children treated for a solid tumor before 2000 in France and before the age of 19 years.

The study is concerned by improving knowledge about the long-term effects caused by cancer and its treatments including adverse health and social outcomes.

The main reason of the FCCSS is to estimate the risk of adverse health and social outcomes that may occur after a cancer treatment and to prevent them by providing adapted follow-up care.

The cohort will be followed for up to 20 years from 2011.


Clinical Trial Description

The main objectives of the FCCSS are to:

- estimate the relationship between doses received (radiotherapy, chemotherapy) at a given organ and risk of second malignancy tumors;

- help identify patients at higher risk;

- compare the mortality occurred among the survivors with the general population;

- investigate the consequences of various intensities of exposure to chemotherapy and/or radiation on health outcomes (such as cardiovascular, cerebrovascular and thyroid diseases, diabetes,…);

- characterize survivors with respect to socioeconomic status and quality of life.

The cohort will be ascertained using:

- the medical records from the treatment centers in order to characterize the childhood cancer, estimate doses of radiotherapy received by all organs and measure the chemotherapy administered;

- the French National Identification Registry and the French Death Registry in order to obtain the vital status and the causes of the deaths for the former patients

- a self-questionnaire that covers the entire future of the survivors (e.g. social status, family network, fertile offspring, access to care, access to bank loans, occupation,...);

- the French National Health Insurance Information System that contains data on all reimbursements for health expenditure including medicinal products as well as outpatient medical and nursing care, prescribed or performed by healthcare professionals.

In an initial cohort, we have already studied the iatrogenic effects of the cancer treatments. We have estimated the doses of ionising radiations delivered by radiotherapy to the target volume and by organs at distance. We found an important role of the radiotherapy and chemotherapy in the risk of a second cancer:

- the cancers occuring after childhood cancer are in excess compared to the general population,

- we studied the relationship between the brain radiation dose and the cerebrovascular mortality,

- there is a high risk of cardiac pathology after anthracyclines administration for a childhood cancer,

- cancer treatments increase the risk of second malignant neoplasms in digestive organs after a very long latency period,

- the risk of thyroid adenoma increased with the radiation dose received by the thyroid during childhood cancer treatment, and plateaued at high doses,

- there is a high long-term mortality risk for all types of second malignant neoplasms whatever the treatment received. ;


Study Design

Observational Model: Cohort, Time Perspective: Retrospective


Related Conditions & MeSH terms


NCT number NCT01620372
Study type Observational
Source Institut National de la Santé Et de la Recherche Médicale, France
Contact Florent F. de Vathaire, Ph.D
Email florent.devathaire@igr.fr
Status Recruiting
Phase N/A
Start date November 2011
Completion date November 2031

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03336931 - PRecISion Medicine for Children With Cancer
Completed NCT03430752 - Comparing the Impact of Cancer on Quality of Life Between Survivors of Childhood Solid Tumors and Leukemia
Active, not recruiting NCT03585465 - Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06208657 - Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer Phase 1/Phase 2
Recruiting NCT01919866 - Safety Study of CD3/CD19 Depleted Haploidentical Stem Cells Phase 1/Phase 2
Terminated NCT01337544 - Haploidentical Stem Cell Transplantation and IL-15 NK Cell Infusion for Paediatric Refractory Solid Tumours Phase 1/Phase 2
Completed NCT02533895 - Cancer Immune Therapy for the Treatment of Refractory Solid Tumours of Childhood Phase 1
Active, not recruiting NCT03445858 - Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults Early Phase 1
Recruiting NCT05504772 - Precision Medicine for Every Child With Cancer
Terminated NCT02624388 - Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) Phase 2
Completed NCT01670175 - Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors Phase 1
Completed NCT03206021 - COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors Phase 1